Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Successes and challenges in designing combination immunotherapy clinical trials for breast cancer

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.05.16
Views: 1590

Prof Leisha Emmens - Johns Hopkins Kimmel Cancer, Baltimore, USA

Dr Leisha Emmens speaks with ecancertv at AACR 2016 about her efforts to shape a course of immunotherapy against, what were previously considered non-immunogenic, breast cancers.

Having identified efficacy of a moderate dose of cyclophosphamide via combination therapy in previous studies, Dr Emmens is now moving forwards with trials of trastuzumab combination therapies for metastatic disease.

Looking forward, she describes her hopes for immunotherapy to offer effective, personalised treatment to all patients and all tumour types.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation